Cointime

ImmunGene

company

About

ImmunGene is a drug discovery and development company, developing monoclonal antibody-based therapeutics to treat cancer and other diseases.

  • Thousand Oaks,California,United States
  • 11 - 50

Highlights

Total Funding Amount
$9M
Funding Rounds
1
Investors
1
Employee Profiles
1

Details

Last Funding Type
Series A
Last Funding Money Raised
$9M
Industries
Biotechnology,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2007
Number Of Employee
11 - 50
Operating Status
Active

ImmunGene is a privately held biotechnology company focused on the development of proprietary antibody-cytokine fusion technology and monoclonal antibody-based therapies to treat cancer, autoimmune disorders, and other diseases. ImmunGene has several programs at various stages of development. ImmunGene is funded by federal government grants including the NIH-SBIR and by private investors including several biotechnology executives.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$9M
ImmunGene has raised a total of $9M in funding over 2 rounds. Their latest funding was raised on Nov 7, 2013 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 7, 2013 Series A $9M 1 Ally Bridge Group — Detail

Investors

Number of Lead Investors
Number of Investors
1
1
ImmunGene is funded by 1 investors. Ally Bridge Group are the most recent investors.
Investor Name Lead Investor Funding Round
Ally Bridge Group Yes Series A

Employee Profiles

Number of Employee Profiles
1
ImmunGene has 1 current employee profiles, including Executive Sanjay D. Khare
Sanjay D. Khare
Executive
Cointime
เนื้อหา
บริษัท